0 181

Cited 3 times in

Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B)

Authors
 Sung Hoon Sim  ;  Jeong Eun Kim  ;  Min Hwan Kim  ;  Yeon Hee Park  ;  Jee Hyun Kim  ;  Koung Jin Suh  ;  Su-Jin Koh  ;  Kyong Hwa Park  ;  Myoung Joo Kang  ;  Mi Sun Ahn  ;  Kyoung Eun Lee  ;  Hee-Jun Kim  ;  Hee Kyung Ahn  ;  Han Jo Kim  ;  Keon Uk Park  ;  Jae Ho Byun  ;  Jin Hyun Park  ;  Gyeong-Won Lee  ;  Keun Seok Lee  ;  Joohyuk Sohn  ;  Kyung Hae Jung  ;  In Hae Park 
Citation
 BREAST, Vol.65 : 172-178, 2022-10 
Journal Title
BREAST
ISSN
 0960-9776 
Issue Date
2022-10
MeSH
Antineoplastic Combined Chemotherapy Protocols / therapeutic use ; Biosimilar Pharmaceuticals* / therapeutic use ; Breast Neoplasms* / pathology ; Dioxolanes ; Female ; Humans ; Physicians* ; Receptor, ErbB-2 ; Trastuzumab
Full Text
https://www.sciencedirect.com/science/article/pii/S0960977622001333
DOI
10.1016/j.breast.2022.08.002
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Min Hwan(김민환) ORCID logo https://orcid.org/0000-0002-1595-6342
Sohn, Joo Hyuk(손주혁) ORCID logo https://orcid.org/0000-0002-2303-2764
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/193377
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links